Literature DB >> 3409235

Effect of hyperthermia on cis-diamminedichloroplatinum(II) (rhodamine 123)2[tetrachloroplatinum(II)] in a human squamous cell carcinoma line and a cis-diamminedichloroplatinum(II)-resistant subline.

T S Herman1, B A Teicher, K N Cathcart, M E Kaufmann, J B Lee, M H Lee.   

Abstract

The effect of concomitant hyperthermia on the cytotoxicities of cis-diamminedichloroplatinum(II) (CDDP), a newly synthesized drug, Pt(Rh-123)2, and its chemical components, K2PtCl4 and rhodamine 123, was examined in vitro in a squamous cell tumor line of human origin (SCC-25) and in a CDDP-resistant subline (SCC-25/CP). No difference in the cytotoxicity of hyperthermia alone was observed between these cell lines. The dose-dependent cytotoxicities of 1-h exposures to CDDP and Pt(Rh-123)2 were markedly increased at 42 degrees C and 43 degrees C in comparison to 37 degrees C, and this effect was of the same magnitude in both cell lines (enhancements of approximately 1.5 logs at 42 degrees C and 2.5 logs at 43 degrees C for CDDP and 1.5 logs at 42 degrees C and greater than 3 logs at 43 degrees C for Pt(Rh-123)2). The use of hyperthermia with CDDP, however, did not lower survivals in the SCC-25/CP cells even to the levels seen in the parent line at 37 degrees C. The cytotoxicities of K2PtCl4 and rhodamine 123 were essentially the same in the CDDP-sensitive and -resistant cells at all temperatures tested. The magnitude of the temperature effect was significantly greater for Pt(Rh-123)2 than for its chemical components. No significant effect on CDDP or Pt(Rh-123)2 accumulation was observed at 42, 43, 44 or 45 degrees C in either cell line. DNA lesions, measured by alkaline elution, were significantly enhanced for CDDP in the SCC-25 cells at 42 degrees C. These results suggest that treatment with hyperthermia and either CDDP or Pt(Rh-123)2 should result in supraadditive anti-tumor effects, although the efficacy of CDDP plus hyperthermia will be significantly less once resistance to CDDP has developed. Since resistance to CDDP does not imply cross-resistance to Pt(Rh-123)2, and since the effect of hyperthermia is somewhat greater for Pt(Rh-123)2 than for CDDP at 43 degrees C, Pt(Rh-123)2 may be more selectively toxic to tumor cells when used with local hyperthermia versus normal cells outside the treated area, especially if resistance to CDDP has already developed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3409235

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  The therapeutic potential of regulated hypothermia.

Authors:  C J Gordon
Journal:  Emerg Med J       Date:  2001-03       Impact factor: 2.740

2.  Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer.

Authors:  P Harter; S Mahner; F Hilpert; I Runnebaum; O Ortmann; A Mustea; J Sehouli; A du Bois; U Wagner
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-03       Impact factor: 2.915

3.  Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells.

Authors:  S Ohno; Z H Siddik; Y Kido; L A Zwelling; J M Bull
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Interaction of platinum complexes of thiazin and xanthene dyes with hyperthermia.

Authors:  T S Herman; B A Teicher; M R Pfeffer; V S Khandekar; E Alvarez Sotomayor
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Heat enhances the cytotoxicity of cis-diamminedichloroplatinum(II) and its analogues cis-1,1-cyclobutane-dicarboxylato(2R)-2-methyl-1,4- butanediammineplatinum(II) and cis-diammine(glycolato)platinum in vitro.

Authors:  I Takahashi; Y Maehara; H Kusumoto; S Kohnoe; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Analysis of the cytotoxic interaction between cisplatin and hyperthermia in a human ovarian carcinoma cell line.

Authors:  E Kimura; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells.

Authors:  J V Hettinga; W Lemstra; C Meijer; W A Dam; D R Uges; A W Konings; E G De Vries; H H Kampinga
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Sequence dependence of the hyperthermic potentiation of carboplatin-induced cytotoxicity and intracellular platinum accumulation in HeLa cells.

Authors:  T Kusumoto; Y Maehara; H Baba; I Takahashi; H Kusumoto; S Ohno; K Sugimachi
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

9.  Cisplatin sensitivity and thermochemosensitisation in thermotolerant cDDP-sensitive and -resistant cell lines.

Authors:  J V Hettinga; W Lemstra; A W Konings; H H Kampinga
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

Review 10.  Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all.

Authors:  Arlene L Oei; Lianne E M Vriend; Johannes Crezee; Nicolaas A P Franken; Przemek M Krawczyk
Journal:  Radiat Oncol       Date:  2015-08-07       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.